No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OII240719C25000
- 0.25
- 0.000.00%
15min DelayClose Jul 3 12:59 ET
0.28High0.11Low
0.11Open0.25Pre Close12 Volume344 Open Interest25.00Strike Price163.00Turnover26.45%IV5.08%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.2578Delta0.2441Gamma120.15Leverage Ratio-0.0145Theta0.0026Rho30.98Eff Leverage0.0162Vega
Intraday
- 5D
- Daily
News
Oceaneering Is Maintained at Buy by Citigroup
Oceaneering Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on Oceaneering International, Raises Price Target to $28
Oceaneering International Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 16.52% Citigroup $25 → $28 Maintains Buy 05/14/2024 -12.61% Barclays $22 → $21 Downgrades Equal
Citi Maintains Oceaneering International(OII.US) With Buy Rating, Raises Target Price to $28
Citi analyst Scott Gruber maintains $Oceaneering International(OII.US)$ with a buy rating, and adjusts the target price from $25 to $28.According to TipRanks data, the analyst has a success rate of 57
Express News | Oceaneering International Inc : Citigroup Raises Target Price to $28 From $25
Express News | Oceaneering Secures Multiple Contractual Agreements For Vessel Services With Global Energy Companies, Covering Operations In The Gulf Of Mexico
Comments
The modest level of insider ownership and lack of insider transactions in the last three months suggest alignment with shareholder interests. However, significant insider selling over the past year could be a red flag for investors.
Insiders At Oceaneering International Sold US$2.5m In Stock, Alluding To Potential WeaknessOceaneering International, Inc.'s transition from loss to profitability justifies its strong share price gain. Despite slowing gains, the company's future financial health remains crucial for shareholders.
Oceaneering International's respectable ROE is overshadowed by its high debt level. Investors should consider the company's performance potential in less favorable credit markets. High ROE without debt typically indicates a high-quality business.
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
17
7
Read more